Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics, Inc. has announced the closing of a transaction whereby its cellular therapy focused subsidiary, TNK Therapeutics, Inc. has acquired Virttu Biologics Limited. Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for the treatment of cancer. Their lead product candidate Seprehvir® has been designed with the ability to specifically target and destroy tumour cells while also stimulating an anti-tumour T-cell mediated immune response. The acquisition of Virttu, will add another clinical-stage asset to Sorrento’s pipeline of immunotherapies.
Read the full press release here.
Mewburn Ellis partner, Richard Clegg and team have been working closely with Virttu Biologics for over 13 years in relation to the building and defending of their IP portfolio